Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Share-based Compensation (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Share-based Compensation readings, the most recent being $3.4 million for Q4 2025.

  • Quarterly Share-based Compensation rose 10.96% to $3.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.4 million through Dec 2025, down 14.26% year-over-year, with the annual reading at $13.4 million for FY2025, 14.26% down from the prior year.
  • Share-based Compensation hit $3.4 million in Q4 2025 for Terns Pharmaceuticals, roughly flat from $3.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $14.1 million in Q3 2023 and bottomed at $1.8 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $3.7 million, with a median of $3.2 million recorded in 2023.
  • The largest annual shift saw Share-based Compensation surged 904.74% in 2021 before it plummeted 70.48% in 2024.
  • Terns Pharmaceuticals' Share-based Compensation stood at $2.6 million in 2021, then increased by 5.37% to $2.7 million in 2022, then increased by 22.14% to $3.3 million in 2023, then decreased by 7.95% to $3.0 million in 2024, then grew by 10.96% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Share-based Compensation are $3.4 million (Q4 2025), $3.3 million (Q3 2025), and $3.0 million (Q2 2025).